News & Views | Telix Pharmaceuticals Limited

Commercial Launch: Illuccix® Now Available to Order in the United States

Telix announces that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), also known as 68Ga-PSMA-11 injection, is now commercially available in the United States.

Change of Composition of the Telix Board of Directors

Telix announces that Tiffany Olson has been appointed to the Board, as a U.S.-based independent Non-Executive Director.

Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®

Telix announces agreement with Xiel for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in the UK and Republic of Ireland

ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment

Telix announces the ZIRCON Phase III study of investigational kidney cancer imaging agent, TLX250-CDx has dosed the target enrolment of 252 patients.

Telix Releases Results for the Year Ended 31 December 2021 and 2021 Annual Report

Telix Pharmaceuticals Limited Releases Full-Year 2021 Results and 2021 Annual Report.

Telix Enters Commercial Distribution Agreement for Illuccix® in Australia

Telix announces a commercial distribution agreement with Global Medical Solutions Australia (GMSA), for Illuccix® in the Australian market

Telix and SHINE partner for Lutetium-177 Supply

Telix announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for lutetium-177

Darren Smith Joins Telix as Deputy Group Chief Financial Officer

Telix is pleased to announce that Darren Smith has joined the Company as Deputy Group Chief Financial Officer.

Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus

Telix signs a commercial distribution agreement with BIOKOSMOS for prostate cancer investigational imaging product Illuccix® in Greek and Cypriot markets.

Telix Completes A$175 Million Placement and Launches A$25 Million SPP

Telix announces a successful $175 million institutional placement and launches Share Purchase Plan to raise up to $25 million.